AmgenvsCAMP4 Therapeutics

AMGN and CAMP stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

CAMP

CAMP4 Therapeutics Corporation

$3.79

Value $299M

-5.25%
CAMP's page

Amgen (AMGN) has a market value of $235B and CAMP4 Therapeutics (CAMP) $299M. Over the last year, with dividends, AMGN moved +31.5% and CAMP +2.2%. Dividend yield: AMGN 2.31%, CAMP none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    CAMP$299M

    AMGN is 785 times CAMP

  • Revenue, 12 months

    AMGN$38.9B

    CAMP$5.3M

    AMGN is 7,313 times CAMP

  • Net income, 12 months

    AMGN$9.4B

    CAMP-$121M

  • Operating margin

    AMGN32.4%

    CAMP-1,001.1%

    1,033.4 points apart

  • ROIC

    AMGN16.2%

    CAMP-86.3%

    102.5 points apart

  • P/E

    AMGN25.0

    CAMP–

  • Dividend yield

    AMGN2.3%

    CAMP0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+31.5%

CAMP+2.1%

100150DecFebAprJunAugOct
Returns by period
PeriodAMGNWith dividendsCAMPWith dividends
1 year since November 19, 2025+31.5%Price +27.2%+2.2%Price +2.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenCAMPCAMP4 Therapeutics

Valuation

AMGNCAMP
Valuation
Price$435.64$3.79
Market value$235B$299M
Enterprise value (EV)$276B$175M
P/E25.0–
P/E, 5-year median23.0–
P/B16.42.8
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNCAMP
Results and growth
Revenue, 12 months$38.9B$5.3M
Net income, 12 months$9.4B-$121M
Free cash flow, 12 months$9.6B-$26M
Earnings per share, 12 months$17.25-$2.14
Revenue growth, year on year10.0%436.5%
Revenue growth a year, past+7.6%over 5 years+216.1%over 2 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNCAMP
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%-1,001.1%
Net margin24.1%-2,276.3%
ROIC16.2%-86.3%
ROE87.8%-248.5%

Balance sheet

AMGNCAMP
Balance sheet
Cash$13.2B$125M
Total debt$54.0B$6.5M
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNCAMP
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or CAMP

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or CAMP4 Therapeutics?

By market value, Amgen ($235B) is about 784.9 times CAMP4 Therapeutics ($299M), at today's prices.

How did AMGN and CAMP stock do over the last 1 years?

Since November 19, 2025, AMGN's price moved +27.2% and CAMP's +2.2%. With dividends: AMGN +31.5% (+31.5% a year), CAMP +2.2% (+2.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or CAMP?

The dividend yield at today's price is 2.31% for Amgen and none for CAMP4 Therapeutics. Over the last twelve months they paid $10.08 and – per share.

Which has the higher profit margins, Amgen or CAMP4 Therapeutics?

Over the last twelve months, the net margin was 24.1% for Amgen and -2,276.3% for CAMP4 Therapeutics, and the operating margin 32.4% and -1,001.1%. Revenue was $38.9B and $5.3M.

Which is the better investment, Amgen or CAMP4 Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.